Replication study of all gout for five discovered loci in Caucasian and NZ Polynesian sample sets
| SNP* | Chr.. | position (bp)† | Gene | A1/A2‡ | Caucasian§ | NZ Polynesian¶ | Meta-analysis** | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frequency of A1 | OR (95% CI) | p Value | Frequency of A1 | OR (95% CI) | p Value | OR (95% CI) | p Value | Heterogeneity | ||||||||
| Cases | Controls | Cases | Controls | Cochran's Q | I2 (%) | |||||||||||
| rs11733284 | 4 | 48028097 | NIPAL1 | A/G | 0.362 | 0.356 | 1.01 (0.86 to 1.18) | 0.896 | 0.251 | 0.270 | 0.92 (0.77 to 1.10) | 0.355 | 0.97 (0.86 to 1.09) | 0.603 | 0.43 | 0.0 |
| rs1165196 | 6 | 25813150 | SLC17A1 | T/C | 0.614 | 0.583 | 1.11 (0.95 to 1.30) | 0.271 | 0.731 | 0.711 | 1.12 (0.93 to 1.35) | 0.266 | 1.11 (0.98 to 1.25) | 0.119 | 0.88 | 0.0 |
| rs11758351 | 6 | 26203910 | HIST1H2BF-HIST1H4E | G/T | 0.141 | 0.158 | 0.86 (0.70 to 1.07) | 0.173 | 0.192 | 0.199 | 0.90 (0.74 to 1.10) | 0.334 | 0.88 (0.77 to 1.02) | 0.0941 | 0.77 | 0.0 |
| rs7903456 | 10 | 88919319 | FAM35A | A/G | 0.737 | 0.699 | 1.18 (1.00 to 1.40) | 0.0462 | 0.351 | 0.333 | 1.16 (0.98 to 1.38) | 0.0997 | 1.17 (1.04 to 1.32) | 9.72×10−3 | 0.85 | 0.0 |
| rs2285340†† | 11 | 64435906 | SLC22A12 | A/G | – | – | – | – | 0.158 | 0.143 | 1.06 (0.84 to 1.35) | 0.634 | – | – | ||
*dbSNP rs number.
†SNP positions are based on NCBI human genome reference sequence build 37.4.
‡A1 is risk-associated allele, and A2 is non-risk-associated allele.
§1319 cases for all gout and 514 controls from Caucasian male population.
¶971 cases for all gout and 565 controls from NZ Polynesian male population.
**Meta-analysis of Caucasian and NZ Polynesian samples.
††rs2285340 is monomorphic in Caucasians.
Chr., chromosome; NZ, New Zealand; SNP, single nucleotide polymorphism.